Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486913 | 0.97 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL11017057 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL6327 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9803775 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9803477 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Bromide SCHEMBL986201 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL146933 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL16192626 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL345000 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL35092 | 0.95 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019174631-A1 | METHOD FOR PREPARING NORSTAT | 上海医药集团股份有限公司 | 2019-09-19 | — | — | WO | claimed |
| EP-3539655-A1 | METHOD FOR PREPARING PRECIOUS METAL ISOLATED ATOMS IN SOLUTION, AND APPLICATIONS THEREOF | Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CN) | 2019-09-18 | — | — | EP | claimed |
| US-10287287-B2 | Process development of a pyridine-containing NK-1 receptor antagonist | ELI LILLY AND COMPANY (US) | 2019-05-14 | — | — | US | claimed |
| US-20180237433-A1 | PROCESS DEVELOPMENT OF A PYRIDINE-CONTAINING NK-1 RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY | 2018-08-23 | — | — | US | claimed |
| WO-2017031215-A1 | PROCESS DEVELOPMENT OF A PYRIDINE-CONTAINING NK-1 RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2017-02-23 | — | — | WO | claimed |
| US-20120157687-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS | PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) | 2012-06-21 | — | — | US | claimed |
| EP-2445882-A1 | PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS | Prime European Therapeuticals S.p.A. in forma abbreviata Euticals S.p.A. (IT) | 2012-05-02 | — | — | EP | claimed |
| EP-2272831-A1 | Process for the preparation of arylpyridinyl compounds | Prime European Therapeuticals S.p.A. (IT) | 2011-01-12 | — | — | EP | claimed |
| WO-2010149356-A1 | PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS | PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) | 2010-12-29 | — | — | WO | claimed |
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | claimed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | claimed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| US-20260109691-A1 | PROCESS FOR MANUFACTURING ALOGABAT | HOFFMANN-LA ROCHE INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12383548-B2 | Antibacterial quinolines | Tecnimede—Sociedade Técnico-Medicinal, SA (PT) | 2025-08-12 | — | — | US | disclosed |
| US-12384132-B2 | Retardation film and method for producing same | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2025-08-12 | — | — | US | disclosed |
| EP-0641755-A1 | Process for the hydrosulphination of olefins | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-08 | — | — | EP | disclosed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109691-A1 | PROCESS FOR MANUFACTURING ALOGABAT | GABRA5, GABRA1, GABRA2 | CYP3A4 834/4885TDP1 2944/4885KDM4E 369/4885 |
| US-12383548-B2 | Antibacterial quinolines | NQO2, RABGGTB, NQO1 | CYP3A4 1596/4885TDP1 2416/4885KDM4E 3330/4885 |
| US-20180237433-A1 | PROCESS DEVELOPMENT OF A PYRIDINE-CONTAINING NK-1 RECEPTOR ANTAGONIST | KLRK1, TACR2, TACR1 | CYP3A4 420/4885TDP1 2725/4885KDM4E 1010/4885 |
| US-10287287-B2 | Process development of a pyridine-containing NK-1 receptor antagonist | KLRK1, TACR2, TACR1 | CYP3A4 420/4885TDP1 2725/4885KDM4E 1010/4885 |
| US-20120157687-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ARYLPYRIDINYL COMPOUNDS | BAZ2A, AOC2, ZRANB2 | CYP3A4 443/4885TDP1 3675/4885KDM4E 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.